1 not yet recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow HER2 IHC3+ Advanced Colorectal Cancer: new trials by email Literature Review of HER2 IHC3+ Advanced Colorectal Cancer trials Research Report on HER2 IHC3+ Advanced Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets - HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 142 | 2026-03-01 | 2026-03-19 |
HMPL-013 (1) · Tablets (1) · Trifluridine (1) · regorafenib (1) · tipiracil (1) · trifluridine tipiracil drug combination (1)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)
China (1)